Xomen-E5 filing
Executive Summary
Xoma submits PLA for monoclonal antibody-based product for treatment of gram negative sepsis, firm announced March 31. Xomen E-5, developed in conjunction with Pfizer, may be used to treat gram negative sepsis, which occurs "in patients who have undergone invasive surgery or trauma or in individuals whose immune systems are compromised." Pfizer will market the product worldwide; U.S. marketing will be handled by its Roerig division.